The cell and gene therapies in rare disorders market is expected to grow at a significantly high rate during the forecast period (2025–2034) and main ...

We recently published a list of 15 Best Fast Growth Stocks To Buy Right Now. In this article, we are going to take a look at ...

Highlights,Sarepta Therapeutics continues to expand its RNA-targeted and gene therapy treatments for rare ...

Arrowhead Pharmaceuticals stock could remain under pressure in the near-term, but improved financial outlook and pipeline ...

The consensus price target for CRISPR Therapeutics AG (NASDAQ:CRSP) has been adjusted from $72.75 to $65, reflecting changes in financial performance and industry developments. Despite a quarterly ...

The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...

Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment ...

The co-chief investment officers at Neuberger Berman see a new dynamic in the stock market as investors move on from inflation worries You have no doubt seen warnings that the U.S. stock market is ...

Solid said that the first patients to receive its Duchenne gene therapy all produced high levels of the target protein, an ...

Sarepta Therapeutics (SRPT) has been beaten down lately with too much selling pressure. While the stock has lost 8.5% over ...